Granulocyte colony-stimulating factor does not improve mortality in severe alcoholic hepatitis: a single-center experience from the United States
Gastroenterology and Hepatology from Bed to Bench,
Vol. 16 No. 1 (2023),
2 January 2023
https://doi.org/10.22037/ghfbb.v16i1.2639
Abstract
Aim: To assess the role of granulocyte colony-stimulating factor (GCSF) in the patients with severe alcoholic hepatitis (SAH) using real world experience in the United States.
Background: There are few effective treatments for severe alcoholic hepatitis, which has a significant fatality rate. GCSF has been associated with improved survival in a small number of Indian studies, while there is a dearth of information from other parts of the globe.
Methods: We performed a single-center retrospective study of consecutive patients admitted to a tertiary care, liver transplant center with severe alcoholic hepatitis from May 2015 to February 2019. The patients receiving GCSF (5μg/kg subcutaneously every 12 hours for 5 consecutive days) (n=12) were compared to the patients receiving standard of care (n=42).
Results: Thirty-day, 90-day and 1-year mortality rates was similar among groups (25% vs. 17%, P=0.58; 41% vs 29%, P=0.30; 41% vs 47%, P=0.44, respectively). There was no difference in liver transplant listing and orthotopic transplantation among groups.
Conclusion: In this real-world, United States-based study, GCSF does not improved survival in the patient with several alcoholic hepatitis compared to standard of care.
- alcoholic hepatitis; granulocyte colony-stimulating factor; liver failure
How to Cite
References
Maddrey WC, Boitnott JK, Bedine MS, Weber Jr. FL, Mezey E, White Jr RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-199.
Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365:1790-1800.
Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015;372:1619-1628.
Buzzetti E, Kalafateli M, Thorburn D, Davidson BR, Thiele M, Lotte Gluud L, et al. Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease). Cochrane Database Syst Review 2017;3:CD011646.
Singh V, Sharma AK, Narasimhan RL, Bhalla A, Sharma N, Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol 2014;109:1417-1422.
Singh V, Keisham A, Bhalla A, Sharma N, Agarwal R, Sharma R, et al. Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis. Clin Gastroenterol Hepatol 2018;16:1650-1656.
Shasthry SM, Sharma MK, Shasthry V, Pande A, Sarin SK. Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized control trial. Hepatology 2019;70:802-811.
Rathi S, Hussaini T, Yoshida EM. Granulocyte colony stimulating factor: a potential therapeutic rescue in severe alcoholic hepatitis and decompensated cirrhosis. Ann Hepatol 2021;20:100211.
- Abstract Viewed: 262 times
- PDF Downloaded: 198 times